Kenna J G, Neuberger J, Davies E, Eddleston A L, Williams R
J Immunol Methods. 1984 Oct 26;73(2):401-13. doi: 10.1016/0022-1759(84)90415-0.
An enzyme-linked immunosorbent assay (ELISA) has been developed for detection of anti-mitochondrial antibodies (AMA) in patients' sera. Results are expressed as a mitochondrial binding index, calculated from binding of patients' antibodies to rabbit liver mitochondrial fraction and total liver homogenate. The incidence of AMA detectable by this method in 22 sera from patients with primary biliary cirrhosis was identical with that obtained by conventional immunofluorescence testing (86%), and there was a highly significant correlation between titres determined by the two methods (r = 0.828; P less than 0.01) although ELISA titres were far higher. AMA were also detectable by ELISA in sera from 9/22 patients with chronic active hepatitis, 1/38 patients with other liver diseases, 3/16 patients with syphilis, 2/16 patients with non-hepatic autoimmune diseases and 0/29 normal blood donors; of these, only 2 chronic active hepatitis sera were positive for AMA by immunofluorescence. The ELISA titre was significantly correlated with the mitochondrial binding index determined at a serum dilution of 1:200 (r = 0.793; P less than 0.01), allowing an estimate of antibody titre to be made from ELISA screening at this single serum dilution. This assay, which is simple and reproducible, may be of value as an objective method of screening for AMA.
已开发出一种酶联免疫吸附测定法(ELISA),用于检测患者血清中的抗线粒体抗体(AMA)。结果以线粒体结合指数表示,该指数根据患者抗体与兔肝线粒体组分及肝匀浆的结合情况计算得出。用此方法在22例原发性胆汁性肝硬化患者血清中检测到AMA的发生率与传统免疫荧光检测法的结果相同(86%),并且两种方法测定的滴度之间存在高度显著的相关性(r = 0.828;P<0.01),尽管ELISA法测定的滴度要高得多。ELISA法还可在9/22例慢性活动性肝炎患者、1/38例其他肝病患者、3/16例梅毒患者、2/16例非肝脏自身免疫性疾病患者的血清中检测到AMA,而在29例正常献血者的血清中未检测到AMA;其中,只有2例慢性活动性肝炎患者的血清通过免疫荧光法检测AMA呈阳性。ELISA滴度与在血清稀释度为1:200时测定的线粒体结合指数显著相关(r = 0.793;P<0.01),这使得在该单一血清稀释度下通过ELISA筛选即可估计抗体滴度。这种简单且可重复的检测方法,作为一种筛选AMA的客观方法可能具有价值。